> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ocular Therapeutix's Chief Strategy Officer Resigns Effective Friday To Become A Private Company's CEO
- URL: https://www.bullished.co/ocular-therapeutixs-chief-strategy-officer-resigns-effective-friday-to-become-a-private-92843121/
- Published: 2026-10-16T20:37:07.000Z
- Updated: 2026-10-28T20:38:13.000Z
- Description: Sanjay Nayak told the company of his decision Wednesday; an 8-K filed Friday says he is leaving to become CEO of a privately held company.
- Author: Matteo Parrino
- Tags: SEC Filings, OCUL, Industry: Healthcare

Ocular Therapeutix chief strategy officer Sanjay Nayak [resigned](https://www.sec.gov/Archives/edgar/data/0001393434/000110465926116617/tm2627709d1%5F8k.htm?ref=bullished.co), effective Friday, to become chief executive of a privately held company, according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed that day. He gave the company notice on Wednesday.

## What the 8-K says

The filing, made under Item 5.02 (the section for departures of certain officers), says Sanjay Nayak, M.B.B.S., Ph.D., [told Ocular Therapeutix on October 14](https://www.sec.gov/Archives/edgar/data/0001393434/000110465926116617/tm2627709d1%5F8k.htm?ref=bullished.co) that he was resigning. The resignation took effect October 16, the same day the company signed and filed the report.

That makes the exit immediate rather than phased. The filing says he is leaving to become CEO of a privately held company and does not name it. Jason S. Robins, the company's chief financial officer, signed the filing.

## Stock and what to watch

Ocular Therapeutix shares closed at $6.87 at Friday's close, down about 7% from $7.38 the prior session, according to market data. The filing was accepted at 4:15 p.m. ET, after that close.

The 8-K does not name a replacement for the strategy role.

The next filing from the company would show whether a successor is named for the chief strategy officer role.

Learn

- [Item 5.02: directors and officers leave or join, or executive pay is set →](https://www.bullished.co/learn/8-k-items-explained/#item-502-directors-and-officers-leave-or-join-or-executive-pay-is-set)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — OCULAR THERAPEUTIX, INC (OCUL)](https://www.sec.gov/Archives/edgar/data/0001393434/000110465926116617/tm2627709d1%5F8k.htm?ref=bullished.co) — SEC EDGAR